Method for treating a synucleinopathy
AssigneeThe Board of Trustees of the University of Illinois
InventorsScott Thomas Brady, Gerardo Andres Morfini
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor.
Claims3
A method for restoring fast axonal transport in a cell which expresses a pathological synuclein protein comprising contacting the cell with an effective amount of an agent that inhibits Protein Kinase C mu or Src-Family Tyrosine Kinase activity and measuring PKC mu or Src-Family Tyrosine Kinase activity, thereby restoring fast axonal transport in the cell, wherein said agent that inhibits Protein Kinase C mu comprises Gö6976, MARCKS peptide, or PKC mu peptide substrate and said agent that inhibits Src-Family Tyrosine Kinase comprises PP2, PP1, Radicicol R2146, Geldanamycin, Herbimycin A, PD173955, SKI-606, or PD162531.
A method for treating a synucleinopathy comprising administering to a subject with a synucleinopathy an effective amount of Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor wherein said Protein Kinase C mu inhibitor comprises Gö6976, MARCKS peptide, or PKC mu peptide substrate and said Src-Family Tyrosine Kinase inhibitor comprises PP2, PP1, Radicicol R2146, Geldanamycin, Herbimycin A, PD173955, SKI-606, or PD162531, and measuring PKC mu or Src-Family Tyrosine Kinase activity thereby treating the synucleinopathy.
Dependencies are inferred from the claim text.